博瑞医药: 民生证券股份有限公司关于博瑞生物医药（苏州）股份有限公司2025年度申请综合授信额度及提供担保事项的核查意见

Overview - The company plans to apply for a comprehensive credit limit of up to 3 billion RMB for the year 2025 to meet its operational needs, including working capital loans and project loans [1][2][24] - The credit will involve mutual guarantees among the company and its subsidiaries within the consolidated financial statements [1][22] Company Details - The company, 博瑞生物医药 (Suzhou) Co., Ltd., is involved in the production of various pharmaceutical forms, including tablets and injections, and has a significant focus on drug research and development [2][3] - As of December 31, 2023, the total assets of 博瑞制药 (Suzhou) Co., Ltd. were 571.92 million RMB, with total liabilities of 294.73 million RMB and net assets of 277.19 million RMB [2][3] - The company reported an operating income of 701.75 million RMB and a net profit of 78.42 million RMB for the year 2023 [2][3] Financial Structure - The company has a total of 113.96 million RMB in guarantees provided to its subsidiaries, which represents 47.59% of the company's audited net assets for 2024 [23][24] - The company has no overdue guarantees as of December 31, 2024 [23] Board Approval - The proposal for the credit application and mutual guarantees was approved during the fourth meeting of the fourth board of directors on April 1, 2025, and will be submitted for shareholder approval [23][24]